Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. Genprex's initial research demonstrated that high TROP2 H-scores and low
Genprex teamed up with a big medical company to figure out which patients might benefit most from their lung cancer treatment. This partnership shows the company is moving forward with testing, which is a sign they're serious about their work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.